Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases (ImmuneSkinBank)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Atopic Dermatitis; Dermatomyositis; Psoriasis; Cutaneous Granulomatosis; Lichen Planus; Cutaneous Lupus; Active Leprosy; Cutaneaous Scleroderma; Hidradenitis Suppurativa; Neutrophilic Dermatosis

Treatments: Other: Sampling

Study type: Observational

Funder types: Other

Identifiers

NCT06599411

APHP240183

Details and patient eligibility

About

Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.

The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.

The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.

Enrollment: 700 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients:

• Age>18 years
• Informed consent signed by the patient
• Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis
• Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification [1], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).

Healthy controls :

• Age>18 years
• Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants
• Informed consent signed by the patient
• Absence of known cutaneous or systemic inflammatory disease.

Exclusion criteria

• Under guardianship or curatorship
• Pregnant or breastfeeding woman
• Lack of affiliation with a social security system
• Systemic treatment in progress or received less than 3 months ago.

Trial design

700 participants in 2 patient groups

Patients

Description:

Affected by inflammatory skin disease

Treatment:

Other: Sampling

Other: Sampling

Controls

Description:

Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants

Treatment:

Other: Sampling

Other: Sampling